Sorrento Therapeutics Inc. (Nasdaq: SRNE) has appointed Amar Singh to be its executive vice president and chief business officer, the late-stage clinical oncology company reported Wednesday.
Singh, who was previously senior vice president and chief business officer at Synta Pharmaceuticals, will be responsible for overseeing Sorrento's partnering activities, according to a release.
Singh has worked more than 25 years in business and commercial development. He joins the company as it continues its work on most advanced cell division inhibitor Cynviloq. He holds a master's degree in business administration from the Stern School of Business at New York University and a bachelor's degree from the University of North Carolina at Chapel Hill.
"Amar joins us at a pivotal phase in our company's growth as we advance Cynviloq into its registrational trial and continue the development of resiniferatoxin," Dr. Henry Ji, president and CEO of Sorrento, said. "His successful track record of initiating and closing complex transactions, in addition to managing strategic alliances, will be particularly useful for both our clinical as well as early-stage programs."
6042 Cornerstone Ct. West Ste., B
San Diego, CA 92121